How Taste Receptors in the Gut Trigger Satiety Peptides That Tell the Brain to Stop Eating | Research

The takeaway

Nutrient and taste receptors on gut cells detect food components and trigger the release of satiety peptides (CCK, GLP-1, PYY) that signal the brain to stop eating — making these receptors promising drug targets for obesity.

Nutrient receptors are the first signal generators for satiety
Gut nutrient sensors occupy a unique position — they both control nutrient absorption and initiate the peptide signaling cascade (CCK, GLP-1, PYY) that tells the brain to stop eating

What the researchers found

The review identifies specific nutrient receptors expressed on enteroendocrine cells in the gut: T1R1/T1R3, calcium-sensing receptor, and GPR93 for amino acids and protein; GPR40, GPR41, GPR43, and GPR120 for fatty acids; and T1R2/T1R3 for sugars. These receptors serve a dual function: regulating nutrient transporter expression to control absorption, and directly stimulating secretion of gastrointestinal peptides (CCK, GLP-1, PYY) into the lamina propria.

These peptide signals are transmitted to brain centers controlling feeding behavior (hypothalamus and nucleus of the solitary tract) primarily via vagal nerve afferents, forming the first signal of satiation. The review also notes that tastant compounds — not just full nutrient molecules — can trigger gut peptide secretion via chemosensory receptors on enteroendocrine cells.

Why it matters

The success of GLP-1 receptor agonist drugs (semaglutide, tirzepatide) for obesity has validated the therapeutic power of gut peptide signaling. This review goes upstream to the source — the nutrient receptors that naturally trigger GLP-1, CCK, and PYY release — suggesting an alternative therapeutic strategy: rather than injecting synthetic peptides, drugs could activate the gut's own nutrient-sensing receptors to enhance endogenous peptide secretion. This could potentially achieve similar appetite-suppressing effects through the body's natural satiety system.

How the study worked

This is a narrative review synthesizing research on gut nutrient sensing, receptor biology, enteroendocrine cell function, and gut-brain peptide signaling. It integrates molecular biology, receptor pharmacology, and neuroscience perspectives.

What this study cannot tell us

As a 2012 review, some receptor characterizations and signaling pathway details have been refined or expanded by subsequent research. The therapeutic potential of targeting nutrient receptors in enteroendocrine cells remains largely unproven in human clinical trials. The review focuses primarily on acute satiation signaling and may not capture the full complexity of chronic appetite regulation. Species differences between animal models and humans in nutrient receptor expression and function were not extensively addressed.

How to read the evidence

This is a narrative review synthesizing basic science and translational research on gut nutrient sensing. While individual studies cited range from in vitro receptor characterization to animal models, the review itself is an expert synthesis rather than new experimental data.

When this study was published

Published in 2012, this review predates the widespread clinical adoption of GLP-1 drugs but accurately predicted the therapeutic importance of gut peptide signaling. Many of its concepts have since been validated by the success of semaglutide and tirzepatide, though some receptor characterizations may have been updated by more recent research.

The bigger picture

This review, published in 2012, was prescient in highlighting the therapeutic potential of gut peptide signaling pathways — a prediction spectacularly validated by the subsequent explosion of GLP-1 drugs. The concept that gut nutrient sensors control peptide secretion has since become central to metabolic research. The idea of targeting nutrient receptors to boost endogenous peptide release remains an active area of drug development, with potential advantages over exogenous peptide administration including more physiological signaling patterns and oral drug delivery possibilities.

Questions still open

Could drugs that activate gut nutrient receptors produce similar weight loss to injectable GLP-1 agonists by boosting endogenous GLP-1 release?
Do individual differences in gut nutrient receptor expression explain why some people feel full faster than others?
Could 'functional foods' designed to activate specific gut nutrient receptors enhance natural satiety and reduce caloric intake?

Common questions

Does the gut really have taste receptors like the tongue?

Yes — many of the same taste receptor proteins found on the tongue are also expressed in the intestine. But instead of creating conscious taste sensations, these gut receptors detect nutrients as food is digested and trigger the release of hormones (CCK, GLP-1, PYY) that signal fullness to the brain. This 'second taste system' is why you feel satisfied after eating even though you can't consciously taste food once you swallow it.

Could this research lead to weight-loss pills that work differently from Ozempic?

Potentially. Instead of injecting synthetic GLP-1 (like semaglutide/Ozempic does), future drugs could activate the gut's own nutrient receptors to boost natural GLP-1 release. This approach could work as a pill, produce more natural signaling patterns, and potentially cause fewer side effects than injecting large amounts of a single peptide. Several companies are exploring this strategy.

Read the original research

Nutrient sensing and signalling by the gut.

The Proceedings of the Nutrition Society, 71(4), 446-55

View on PubMed ↗Publisher’s paper ↗

Citation

Rasoamanana, Rojo; Darcel, Nicolas; Fromentin, Gilles; Tomé, Daniel. (2012). Nutrient sensing and signalling by the gut.. The Proceedings of the Nutrition Society, 71(4), 446-55. https://doi.org/10.1017/S0029665112000110